Known targets — ChEMBL curated mechanism
DRD2DRD3DRD4GNRHRHRH1HTR2AHTR2CSLC6A2SLC6A4SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Pamoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.56 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.56 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.56 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.56 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.56 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.56 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL21834068 | 1.00 | SLC6A4 (0.56) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL517502 | 0.95 | SLC6A4 (0.51) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL16222836 | 0.93 | SLC6A4 (0.63) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL517584 | 0.92 | SLC6A4 (0.47) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Imipramine SCHEMBL518586 | 0.88 | KMT2A (0.44) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Imipramine SCHEMBL2098515 | 0.84 | LMNA (0.62) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL15533092 | 0.83 | SLC6A4 (0.48) | SLC6A4MAPTHRH1LMNAADORA3 | |
| SCHEMBL5608291 | 0.82 | SLC6A4 (0.47) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Imipramine SCHEMBL4283852 | 0.80 | SLC6A4 (0.71) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Imipramine SCHEMBL20644144 | 0.77 | SLC6A4 (0.83) | SLC6A4MAPTHRH1LMNAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230248737-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS OR SYMPTOMS THEREOF | PSYRX LTD. (IL) | 2023-08-10 | — | — | US | claimed |
| EP-4175643-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS OR SYMPTOMS THEREOF | Psyrx Ltd. (IL) | 2023-05-10 | — | — | EP | claimed |
| US-20230140798-A1 | SYNTHETIC PEPTIDES DIRECTED AGAINST THE METABOTROPIC GLUTAMATE RECEPTOR 5 | LACTOCORE INC (US) | 2023-05-04 | — | — | US | claimed |
| EP-4135741-A1 | SYNTHETIC PEPTIDES FOR MODULATING THE METABOTROPIC GLUTAMATE RECEPTOR 5 | Lactocore, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| CN-115379847-A | Synthetic peptides for modulating metabotropic glutamate receptor 5 | 拉托科公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220175873-A1 | SYNTHETIC NEUROMODULATORY PEPTIDES | LACTOCORE, INC. | 2022-06-09 | — | — | US | claimed |
| EP-3938375-A2 | SYNTHETIC NEUROMODULATORY PEPTIDES | Lactocore, Inc. (US) | 2022-01-19 | — | — | EP | claimed |
| US-20060148785-A1 | Medicine for treating gastrointestinal disorder including fecal incontinence | LUNDEEN JAMES E | 2006-07-06 | — | — | US | claimed |
| US-20060148781-A1 | Method and medicine for treating gastrointestinal disorder in a non-human mammal | SIR ISAAC NEWTON ENTERPRISES LLC | 2006-07-06 | — | — | US | claimed |
| US-20050113365-A1 | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome | SIR ISAAC NEWTON ENTERPRISES LLC (US) | 2005-05-26 | — | — | US | claimed |
| WO-2004100899-A2 | USE OF SECRETIN IN TREATMENTS OF DISORDERS ASSOCIATED WITH THE AMYGDALA | THE MCLEAN HOSPITAL CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| US-20030139698-A1 | Medicated wrap | HYSON MORTON I (US) | 2003-07-24 | — | — | US | claimed |
| EP-1309301-A1 | MEDICATED WRAP | Hyson, Morton I. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020035105-A1 | Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain | ENDO PHARMACEUTICALS INC. | 2002-03-21 | — | — | US | claimed |
| WO-2001080797-A1 | MEDICATED WRAP | HYSON MORTON I (US) | 2001-11-01 | — | — | WO | claimed |
| EP-0980247-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050044-A1 | COMPOSITION AND METHOD COMBINING AN ANTIDEPRESSANT WITH AN NMDA RECEPTOR ANTAGONIST, FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113365-A1 | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome | SI, TPH1, FABP2 | SLC6A4 27/4885HRH1 42/4885DRD2 71/4885 |
| US-20230248737-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS OR SYMPTOMS THEREOF | GRIN2C, HTR5A, HTR2A | SLC6A4 72/4885HRH1 923/4885DRD2 32/4885 |
| US-20060148785-A1 | Medicine for treating gastrointestinal disorder including fecal incontinence | SI, SLC10A2, HNMT | SLC6A4 21/4885HRH1 272/4885DRD2 586/4885 |
| US-20060148781-A1 | Method and medicine for treating gastrointestinal disorder in a non-human mammal | SI, FABP2, FABP6 | SLC6A4 24/4885HRH1 69/4885DRD2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.